Table 2.
Characteristics of HCC by Insurance Status
| Uninsured | Insured | P value | ||||
|---|---|---|---|---|---|---|
| Insurance status | 53 | 32.92% | 108 | 67.08% | ||
| Age | Median (IQR) | 58 (8.25) | 59 (10) | 0.0717 | ||
| Sex | Female | 10 | 18.87% | 14 | 12.96% | 0.3229 |
| Male | 43 | 81.13% | 94 | 87.04% | ||
| Ethnicity | African American | 8 | 15.69% | 16 | 15.24% | 0.4981 |
| Asian | 2 | 3.92% | 3 | 2.86% | ||
| Hispanic | 26 | 50.98% | 47 | 44.76% | ||
| Native American | 0 | 0.00% | 6 | 5.71% | ||
| White | 15 | 29.41% | 33 | 31.43% | ||
| BMI | Median (IQR) | 27 (5.49) | 27.45 (7.68) | 0.2829 | ||
| Surveillance | Surveillance | 19 | 35.85% | 56 | 51.85% | 0.0558 |
| Spontaneous | 34 | 64.15% | 52 | 48.15% | ||
| Initial MELD | Median (IQR) | 12 (6.5) | 10 (6) | 0.1386 | ||
| Final MELD | Median (IQR) | 20 (11.75) | 15 (10.25) | 0.0053 | ||
| Liver Biopsy | No | 33 | 62.26% | 71 | 65.74% | 0.6647 |
| Yes | 20 | 37.74% | 37 | 34.26% | ||
| Milan criteria | No | 41 | 77.36% | 52 | 48.15% | 0.0004 |
| Yes | 12 | 22.64% | 56 | 51.85% | ||
| Transplant referral | No | 43 | 84.31% | 63 | 61.76% | 0.0023 |
| Yes | 8 | 15.69% | 39 | 38.24% | ||
| Listed for Transplant | No | 51 | 98.08% | 97 | 93.27% | 0.2071 |
| Yes | 1 | 1.92% | 7 | 6.73% | ||
| Treatment for HCC | No | 28 | 52.83% | 36 | 33.33% | 0.0175 |
| Yes | 25 | 47.17% | 72 | 66.67% | ||
| IR RFA | No | 48 | 90.57% | 74 | 68.52% | 0.0022 |
| Yes | 5 | 9.43% | 34 | 31.48% | ||
| IR TACE | No | 42 | 79.25% | 68 | 62.96% | 0.0369 |
| Yes | 11 | 20.75% | 40 | 37.04% | ||
| Sorafenib | No | 44 | 98.11% | 94 | 87.04% | 0.4935 |
| Yes | 9 | 1.89% | 14 | 12.96% | ||
| Surgical RFA | No | 52 | 92.45% | 104 | 96.30% | 0.5323 |
| Yes | 1 | 7.55% | 4 | 3.70% | ||
| Surgical Resection | No | 49 | 92.45% | 102 | 95.33% | 0.5924 |
| Yes | 4 | 7.55% | 5 | 4.67% | ||
| Hospice care | No | 18 | 38.30% | 61 | 61.00% | 0.01 |
| Yes | 29 | 61.70% | 39 | 39.00% | ||
Abbreviations: BMI, body mass index; d, days; HCC, hepatocellular carcinoma; IQR, interquartile range; MELD, Model for End Stage Liver Disease; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.